WinstonWınston
Medios AG logo

Medios AG

ILM1.DE
41
Medical - Distribution · Healthcare
Also trades as: 0QB4.L
Price
€11.54
+0.40 (+3.59%)
Market Cap
€294.3M
Exchange
Frankfurt Stock Exchange
Winston Score
41
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 12, 2026 · filings through Mar 31, 2026

Share count rising — dilution

+24.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 20.2M (2021) → 25.0M (2025)

Medios AG is a German healthcare company that makes and distributes specialty medicines. It focuses on personalized therapies — drugs that are custom-made for individual patients — and supplies these to pharmacies and hospitals across Germany. The company is one of the larger players in Germany's growing market for specialty pharmaceuticals, including treatments for cancer, HIV, and rare diseases.

Medios earns money by manufacturing compounded drugs in its own facilities and by distributing specialty medicines to partner pharmacies. It operates almost entirely within Germany, with annual revenues in the hundreds of millions of euros. Its main competitive advantage is its integrated model — combining manufacturing and distribution under one roof — which gives it some pricing power with pharmacy partners. However, the company's thin margins leave little room for error, and its growth depends heavily on expanding its network of partner pharmacies and increasing the volume of high-value compounded prescriptions it fills.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+8.9% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-20.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

67.3%ownership

Rising

Insiders increasing their stake — aligned with shareholders

Cash Position

Cash flow positive

$95M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Medios AG is growing revenue at 9% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
4.3%
Thin — 4.3% gross margin
Operating Margin
1.8%
Thin — 1.8% operating margin
ROCE
1.3%
Weak — 1.3% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+11.0%
Steady sales growth (+11.0% YoY)
EPS YoY
-7.0%
Earnings shrinking (-7.0% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
413%
Turns 413% of profit into real cash
FCF Margin
2.3%
Thin free cash flow (2.3%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.39
Conservative — low debt load (0.39)
Interest Cover
2.44x
Tight — interest eats into profit (2.4x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
21.0x
Growth-priced — P/E 21.0

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+14.6
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (21.0 → 6.4)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial